Historical CMC projects that Eviva Pharma have worked on include experience of numerous dosage forms, from pre-clinical to late phase products, and as such offer consultancy that is broad based.

Further details of these historical CMC projects can be found below.

PRE-CLINICAL
Type of CompoundDose FormActivity
Synthetic compoundOralAnalytical
Kinase inhibitorIVAnalytical
Kallikrein inhibitorOralAnalytical
PHASE I
Type of CompoundDose FormActivity
Monoclonal antibodyIV, AqueousAnalytical
Tetra peptideInjection, AqueousAnalytical
Monoclonal antibodyIV, AqueousAnalytical
Monoclonal antibodyIV, AqueousAnalytical
Hsp inhibitorIV, LyophilisedFormulation development/Analytical
PeptideSC, AqueousFormulation development
Monoclonal antibodyIV, AqueousAnalytical
Killed bacterial vaccineOral, SuspensionFormulation development/Analytical
T-cell inhibitorOralAnalytical
Thrombin inhibitorIVFormulation development
PHASE II
Type of CompoundDose FormActivity
Monoclonal antibodyIV, AqueousAnalytical
Killed bacterial vaccineOral, SuspensionFormulation development/Analytical
Conjugated angiotensin peptideInjection, AqueousAnalytical
Synthetic compound derived from plantsIA, Surfactant solutionFormulation development
SyntheticIV, AqueousFormulation development
Synthetic MDROral, soft gel capsuleFormulation development
Synthetic MDRIV, Co-solventFormulation development
PHASE III/IV
Type of CompoundDose FormActivity
Active metabolite of morphineIV, AqueousAnalytical
Cocaine conjugateInjection, AqueousAnalytical
PAF antagonistIV, AqueousFormulation development
SyntheticOral, TabletExpert report
Synthetic phosphodiesterase inhibitor IV, Co-solventFormulation development
Semi synthetic glycopeptide IV, LyophilisedFormulation development
SyntheticOral, TabletExpert report
MARKETED
Type of CompoundDose FormActivity
Anti-venomIV, LyophilisedAnalytical